These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1065 related articles for article (PubMed ID: 11103813)
1. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813 [TBL] [Abstract][Full Text] [Related]
2. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295 [TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733 [TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962 [TBL] [Abstract][Full Text] [Related]
5. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644 [TBL] [Abstract][Full Text] [Related]
6. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188 [TBL] [Abstract][Full Text] [Related]
7. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. Siders WM; Wright PW; Hixon JA; Alvord WG; Back TC; Wiltrout RH; Fenton RG J Immunol; 1998 Jun; 160(11):5465-74. PubMed ID: 9605149 [TBL] [Abstract][Full Text] [Related]
10. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma. Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345 [TBL] [Abstract][Full Text] [Related]
11. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461 [TBL] [Abstract][Full Text] [Related]
12. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Hall SJ; Sanford MA; Atkinson G; Chen SH Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645 [TBL] [Abstract][Full Text] [Related]
13. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164 [TBL] [Abstract][Full Text] [Related]
15. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Tsung K; Dolan JP; Tsung YL; Norton JA Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763 [TBL] [Abstract][Full Text] [Related]
16. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121 [TBL] [Abstract][Full Text] [Related]
17. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related]
18. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. Fogler WE; Volker K; Watanabe M; Wigginton JM; Roessler P; Brunda MJ; Ortaldo JR; Wiltrout RH J Immunol; 1998 Dec; 161(11):6014-21. PubMed ID: 9834083 [TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy. Wang H; Dai J; Hou S; Qian W; Li B; Ma J; Fan X; Zhao J; Yang S; Sang H; Yang Q; Wang R; Guo Y Cancer Gene Ther; 2005 Sep; 12(9):769-77. PubMed ID: 15877081 [TBL] [Abstract][Full Text] [Related]
20. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. Fort MM; Leach MW; Rennick DM J Immunol; 1998 Oct; 161(7):3256-61. PubMed ID: 9759840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]